Francesco Paolo Fiorentino

Dr. Francesco Paolo Fiorentino

orcid

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2011 in Fertility and Sterility
Verified
Journal Article
Closed access
APAntonino Perino
Antonino Perino
LGLucia Giovannelli
Lucia Giovannelli
RSRosaria Schillaci
Rosaria Schillaci
GRGiovanni Ruvolo
Giovanni Ruvolo
FFFrancesco Paolo Fiorentino
Francesco Paolo Fiorentino
PAPiero Ammatuna
Piero Ammatuna

18 April 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
FFFrancesco Paolo Fiorentino
Francesco Paolo Fiorentino
ETElvan Tokgün
Elvan Tokgün
SSSònia Solé-Sánchez
Sònia Solé-Sánchez
SGSabrina Giampaolo
Sabrina Giampaolo
OTOnur Tokgün
Onur Tokgün
JYJun Yokota
Jun Yokota
Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation

1 June 2007 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
VAV. Agnese
V. Agnese
VBV. Bazan
V. Bazan
FFFrancesco Paolo Fiorentino
Francesco Paolo Fiorentino
DFD. Fanale
D. Fanale
GBG. Badalamenti
G. Badalamenti
ARA. Russo
A. Russo
Recently, new chemotherapy agents which target the non-structural components of mitosis have been developed. An important protein involved in several mitotic phases is the Aurora-A protein. By means of the phosphorylation of different substrates, Aurora-A regulates the correct development of the various phases of mitosis. The kinase activity of this protein makes Aurora-A an excellent candidate as an oncogene. The first data of Aurora-A involvement in cancer regarded the identification of Aurora-A overexpression in primary breast and colon tumour samples. With regard to the predictive role of Aurora-A, it has been shown that its overexpression disrupts the spindle checkpoint activated by paclitaxel (Taxol) or nocodazole treatment, thus inducing the cells to become resistant to these drugs. The development therefore of small molecules with an Aurora-A inhibition function may make it possible to reduce or block the oncogenic activity of Aurora-A and in addition may improve the survival of oncological patients showing resistance to paclitaxel or nocodazole treatment. Three novel Aurora kinase inhibitors have recently been described—Hesperadin, ZM447439 and VX-680. All these three drugs have been designed to target the ATP-binding site of Aurora kinase, so they inhibit all three Aurora kinase family members showing a similar phenotype when tested in cell-based assays. Among these three different molecules, VX-680 has shown promising results in in vitro and in vivo studies. In conclusion, it is clear that we are entering a new era in anti-mitotic therapy with the identification and now clinical translation of new targets in mitosis beyond tubulin but many questions remain with regard to Aurora function.

4 April 2011 in Journal of Cellular Physiology
Verified
Journal Article
Closed access
PDF file
FFFrancesco Paolo Fiorentino
Francesco Paolo Fiorentino
Antonio GiordanoAntonio Giordano
Antonio Giordano

14 October 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
FKFuyumi Kato
Fuyumi Kato
FFFrancesco Paolo Fiorentino
Francesco Paolo Fiorentino
AAAndreu Alibés
Andreu Alibés
Manuel PeruchoManuel Perucho
Manuel Perucho
MSMontse Sánchez-Céspedes
Montse Sánchez-Céspedes
JYJun Yokota
Jun Yokota
MYCL is a target of a BET bromodomain inhibitor, JQ1, on growth suppression efficacy in small cell lung cancer cells

14 September 2012 in Cell Cycle
Verified
Journal Article
Open access
IMIrene Marchesi
Irene Marchesi
FFFrancesco Paolo Fiorentino
Francesco Paolo Fiorentino
FRFlavio Rizzolio
Flavio Rizzolio
Antonio GiordanoAntonio Giordano
Antonio Giordano
Luigi BagellaLuigi Bagella
Luigi Bagella
Rhabdomyosarcoma (RMS) is a pediatric tumor that arises from muscle precursor cells. RMS cells express several markers of early myogenic differentiation, but they fail to complete both differentiation program and cell cycle arrest, resulting in uncontrolled proliferation and incomplete myogenesis. Previous studies showed that EZH2, which is involved in both differentiation and cancer progression, is overexpressed in RMS, but a functional binding between its expression and its functional role in tumor formation or progression has not yet been demonstrated. We hypothesized that EZH2 is a key regulator of muscular differentiation program in RMS cells. In this study, we demonstrated that EZH2 directly binds muscle specific genes in RD cells. Silencing of EZH2 promotes the recruitment of a multiprotein complex at muscle-specific promoters, their transcriptional activation and protein expression. Moreover, we demonstrated that EZH2 is directly involved in transcriptional repression of MyoD, the main factor promoting myogenesis. EZH2 ablation induces MyoD activation the recovery of its binding on muscle-specific genes.